Cargando…

Hyperlipidemia Caused by Voriconazole: A Case Report

Voriconazole has been widely used in clinical practice for nearly 20 years. The adverse reactions caused by voriconazole have been reported gradually, such as visual impairment, hepatotoxicity, skin rash. At present, there are few reports about triazole antifungal drugs causing the increase of trigl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jiasheng, Chen, Na, Yao, Yake, Zhou, Jianying, Zhou, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882454/
https://www.ncbi.nlm.nih.gov/pubmed/33603412
http://dx.doi.org/10.2147/IDR.S301198
_version_ 1783651049897197568
author Wu, Jiasheng
Chen, Na
Yao, Yake
Zhou, Jianying
Zhou, Hua
author_facet Wu, Jiasheng
Chen, Na
Yao, Yake
Zhou, Jianying
Zhou, Hua
author_sort Wu, Jiasheng
collection PubMed
description Voriconazole has been widely used in clinical practice for nearly 20 years. The adverse reactions caused by voriconazole have been reported gradually, such as visual impairment, hepatotoxicity, skin rash. At present, there are few reports about triazole antifungal drugs causing the increase of triglyceride and total cholesterol. Thus, the present study reported a case of chronic pulmonary aspergillosis with significantly increased blood lipids after treatment with voriconazole. In this case, the patient’s total cholesterol was normal, and triglyceride was 2.64 times of the upper limit of the reference value at the time of admission. On the 30th day after oral administration of voriconazole 200mg q12h, triglyceride and total cholesterol were 4.55 times and 3.31 times of the baseline levels, respectively, with the trough concentration of voriconazole of 6.6 μ g/mL. After 28 days of voriconazole withdrawal and itraconazole administration, triglyceride decreased to 1.45 times of baseline level and total cholesterol decreased to the normal range. After another 24 days of treatment with voriconazole 200mg q12h, triglyceride increased again to 3.25 times of the baseline level and cholesterol was within the normal range. At the same time, the trough concentration of voriconazole was 3.2 μ g/mL. After 14 days of treatment with voriconazole 100mg q12h, the triglyceride level recovered to the baseline level, with the trough concentration of voriconazole of 1.5 μ g/mL. The Naranjo′s rating scale was used, the final score was 10 points, indicating that the causal relationship between voriconazole and dyslipidemia was positive, which was likely to be related to the trough concentration of voriconazole.
format Online
Article
Text
id pubmed-7882454
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78824542021-02-17 Hyperlipidemia Caused by Voriconazole: A Case Report Wu, Jiasheng Chen, Na Yao, Yake Zhou, Jianying Zhou, Hua Infect Drug Resist Case Report Voriconazole has been widely used in clinical practice for nearly 20 years. The adverse reactions caused by voriconazole have been reported gradually, such as visual impairment, hepatotoxicity, skin rash. At present, there are few reports about triazole antifungal drugs causing the increase of triglyceride and total cholesterol. Thus, the present study reported a case of chronic pulmonary aspergillosis with significantly increased blood lipids after treatment with voriconazole. In this case, the patient’s total cholesterol was normal, and triglyceride was 2.64 times of the upper limit of the reference value at the time of admission. On the 30th day after oral administration of voriconazole 200mg q12h, triglyceride and total cholesterol were 4.55 times and 3.31 times of the baseline levels, respectively, with the trough concentration of voriconazole of 6.6 μ g/mL. After 28 days of voriconazole withdrawal and itraconazole administration, triglyceride decreased to 1.45 times of baseline level and total cholesterol decreased to the normal range. After another 24 days of treatment with voriconazole 200mg q12h, triglyceride increased again to 3.25 times of the baseline level and cholesterol was within the normal range. At the same time, the trough concentration of voriconazole was 3.2 μ g/mL. After 14 days of treatment with voriconazole 100mg q12h, the triglyceride level recovered to the baseline level, with the trough concentration of voriconazole of 1.5 μ g/mL. The Naranjo′s rating scale was used, the final score was 10 points, indicating that the causal relationship between voriconazole and dyslipidemia was positive, which was likely to be related to the trough concentration of voriconazole. Dove 2021-02-10 /pmc/articles/PMC7882454/ /pubmed/33603412 http://dx.doi.org/10.2147/IDR.S301198 Text en © 2021 Wu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Wu, Jiasheng
Chen, Na
Yao, Yake
Zhou, Jianying
Zhou, Hua
Hyperlipidemia Caused by Voriconazole: A Case Report
title Hyperlipidemia Caused by Voriconazole: A Case Report
title_full Hyperlipidemia Caused by Voriconazole: A Case Report
title_fullStr Hyperlipidemia Caused by Voriconazole: A Case Report
title_full_unstemmed Hyperlipidemia Caused by Voriconazole: A Case Report
title_short Hyperlipidemia Caused by Voriconazole: A Case Report
title_sort hyperlipidemia caused by voriconazole: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882454/
https://www.ncbi.nlm.nih.gov/pubmed/33603412
http://dx.doi.org/10.2147/IDR.S301198
work_keys_str_mv AT wujiasheng hyperlipidemiacausedbyvoriconazoleacasereport
AT chenna hyperlipidemiacausedbyvoriconazoleacasereport
AT yaoyake hyperlipidemiacausedbyvoriconazoleacasereport
AT zhoujianying hyperlipidemiacausedbyvoriconazoleacasereport
AT zhouhua hyperlipidemiacausedbyvoriconazoleacasereport